3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Lung Neoplasms
4
Non Small Cell Lung Cancer Metastatic
3
Neoplasms
2
Recurrence
1
Neoplasm Metastasis
1
Neoadjuvant Non-Small Cell Lung Cancer
1
Lymphoma, Large-Cell, Anaplastic
1
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
1
Advanced Non-Small Cell Lung Cancer
1
ALK Positive Non-small Cell Lung Cancer
1
Interventions
Cyclophosphamide
58
Dexamethasone
50
Rituximab
39
Peripheral Blood Stem Cell Transplantation
29
Paclitaxel
29
Lenalidomide
28
fludarabine phosphate
27
Gemcitabine
26
Etoposide
26
Bortezomib
26
Cytarabine
25
Busulfan
24
pembrolizumab
21
Radiotherapy
21
Bevacizumab
21
Carboplatin
20
Mycophenolic Acid
19
Melphalan
19
Cisplatin
19
Filgrastim
18
pomalidomide
17
fludarabine
17
Oxaliplatin
17
Antilymphocyte Serum
17
Cyclosporine
16
Tacrolimus
15
Methotrexate
15
Whole-Body Irradiation
14
Methylprednisolone
13
Bendamustine Hydrochloride
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recurrence
×
lorlatinib
×
Clear all
NCT03505554
2023-08-07
CRU3
University of Milano Bicocca
Phase 2
Unknown
12 enrolled